|
Gene: EPHA4 |
Gene summary for EPHA4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | EPHA4 | Gene ID | 2043 |
Gene name | EPH receptor A4 | |
Gene Alias | EK8 | |
Cytomap | 2q36.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R452 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2043 | EPHA4 | CCI_1 | Human | Cervix | CC | 8.54e-10 | 5.45e-01 | 0.528 |
2043 | EPHA4 | CCI_3 | Human | Cervix | CC | 5.89e-03 | 5.91e-01 | 0.516 |
2043 | EPHA4 | Tumor | Human | Cervix | CC | 2.81e-05 | 2.79e-01 | 0.1241 |
2043 | EPHA4 | sample3 | Human | Cervix | CC | 4.30e-11 | 2.96e-01 | 0.1387 |
2043 | EPHA4 | T3 | Human | Cervix | CC | 3.59e-13 | 2.98e-01 | 0.1389 |
2043 | EPHA4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.56e-02 | -2.55e-01 | 0.0155 |
2043 | EPHA4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.24e-08 | -5.56e-01 | -0.1808 |
2043 | EPHA4 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.32e-06 | -3.34e-01 | -0.1464 |
2043 | EPHA4 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.83e-03 | -3.27e-01 | -0.1001 |
2043 | EPHA4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.22e-21 | -5.84e-01 | 0.3859 |
2043 | EPHA4 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.55e-06 | -6.21e-01 | 0.2585 |
2043 | EPHA4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.32e-30 | -6.35e-01 | 0.3005 |
2043 | EPHA4 | F007 | Human | Colorectum | FAP | 1.29e-02 | -3.67e-01 | 0.1176 |
2043 | EPHA4 | A002-C-010 | Human | Colorectum | FAP | 1.98e-02 | -1.20e-01 | 0.242 |
2043 | EPHA4 | A015-C-203 | Human | Colorectum | FAP | 1.15e-17 | -3.31e-01 | -0.1294 |
2043 | EPHA4 | A015-C-204 | Human | Colorectum | FAP | 8.55e-06 | -3.61e-01 | -0.0228 |
2043 | EPHA4 | A002-C-201 | Human | Colorectum | FAP | 7.90e-07 | -2.01e-01 | 0.0324 |
2043 | EPHA4 | A002-C-203 | Human | Colorectum | FAP | 6.90e-04 | -3.04e-01 | 0.2786 |
2043 | EPHA4 | A001-C-119 | Human | Colorectum | FAP | 1.57e-02 | -3.53e-01 | -0.1557 |
2043 | EPHA4 | A001-C-108 | Human | Colorectum | FAP | 8.90e-09 | -3.14e-01 | -0.0272 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:190336210 | Cervix | CC | regulation of cellular protein catabolic process | 72/2311 | 255/18723 | 5.98e-12 | 2.10e-09 | 72 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:190305010 | Cervix | CC | regulation of proteolysis involved in cellular protein catabolic process | 60/2311 | 221/18723 | 1.82e-09 | 1.98e-07 | 60 |
GO:001095210 | Cervix | CC | positive regulation of peptidase activity | 54/2311 | 197/18723 | 8.06e-09 | 6.99e-07 | 54 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
GO:001095010 | Cervix | CC | positive regulation of endopeptidase activity | 48/2311 | 179/18723 | 1.12e-07 | 5.71e-06 | 48 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:00107699 | Cervix | CC | regulation of cell morphogenesis involved in differentiation | 31/2311 | 96/18723 | 2.43e-07 | 1.05e-05 | 31 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa043604 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa043605 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa043606 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
hsa043607 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa043608 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
hsa0436011 | Lung | IAC | Axon guidance | 34/1053 | 182/8465 | 9.31e-03 | 3.62e-02 | 2.41e-02 | 34 |
hsa0436021 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
hsa0436031 | Lung | AIS | Axon guidance | 34/961 | 182/8465 | 2.22e-03 | 1.37e-02 | 8.80e-03 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Cervix | CC |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | Cervix | CC |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | Cervix | CC |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | Cervix | CC |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | CRC | AD |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | AD |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | AD |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | AD |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | ADJ |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | ADJ |
EFNB1 | EPHA4 | EFNB1_EPHA4 | EPHB | CRC | ADJ |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | FAP |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | FAP |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | Healthy |
EFNA5 | EPHA4 | EFNA5_EPHA4 | EPHA | CRC | Healthy |
EFNB2 | EPHA4 | EFNB2_EPHA4 | EPHB | CRC | Healthy |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | MSI-H |
EFNA3 | EPHA4 | EFNA3_EPHA4 | EPHA | CRC | MSI-H |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA4 | SNV | Missense_Mutation | novel | c.2701N>A | p.Ala901Thr | p.A901T | P54764 | protein_coding | tolerated(0.22) | benign(0) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
EPHA4 | SNV | Missense_Mutation | novel | c.2546N>A | p.Cys849Tyr | p.C849Y | P54764 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
EPHA4 | SNV | Missense_Mutation | novel | c.1915N>T | p.Arg639Cys | p.R639C | P54764 | protein_coding | tolerated(0.14) | probably_damaging(1) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
EPHA4 | SNV | Missense_Mutation | c.376N>C | p.Tyr126His | p.Y126H | P54764 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4371-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EPHA4 | SNV | Missense_Mutation | c.1720N>G | p.Ser574Gly | p.S574G | P54764 | protein_coding | tolerated(0.41) | benign(0.05) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EPHA4 | SNV | Missense_Mutation | c.2794N>G | p.Phe932Val | p.F932V | P54764 | protein_coding | deleterious(0) | possibly_damaging(0.673) | TCGA-BR-8588-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EPHA4 | SNV | Missense_Mutation | c.316N>T | p.Arg106Trp | p.R106W | P54764 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
EPHA4 | SNV | Missense_Mutation | c.746C>T | p.Ala249Val | p.A249V | P54764 | protein_coding | tolerated(0.07) | probably_damaging(0.914) | TCGA-BR-A4IY-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
EPHA4 | SNV | Missense_Mutation | c.2216A>T | p.Asp739Val | p.D739V | P54764 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-CD-8527-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | epirubicin | PD | |
EPHA4 | SNV | Missense_Mutation | c.764T>C | p.Val255Ala | p.V255A | P54764 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2043 | EPHA4 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TYROSINE KINASE | inhibitor | CHEMBL24828 | VANDETANIB | |
2043 | EPHA4 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TYROSINE KINASE | inhibitor | 249565821 |
Page: 1 |